Chevy Chase Trust Holdings LLC Acquires 5,393 Shares of United Therapeutics Corporation $UTHR

Key Points

• Chevy Chase Trust Holdings LLC increased its stake in United Therapeutics Corporation by 23.8%, acquiring an additional 5,393 shares, bringing its total holdings to 28,057 shares valued at approximately $8.06 million.
• United Therapeutics reported a net margin of 40.36% and a return on equity of 18.73%, with quarterly revenue of $798.60 million, despite missing analysts' expectations.
• Multiple brokerages have recently adjusted their price targets for United Therapeutics, with ranges between $330.00 and $580.00, indicating a general optimistic outlook with a consensus price target of $461.62.

Chevy Chase Trust Holdings LLC increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 23.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 28,057 shares of the biotechnology company's stock after acquiring an additional 5,393 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.06% of United Therapeutics worth $8,062,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. Kingswood Wealth Advisors LLC lifted its stake in shares of United Therapeutics by 16.0% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 741 shares of the biotechnology company's stock worth $228,000 after acquiring an additional 102 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in shares of United Therapeutics by 31.7% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 9,179 shares of the biotechnology company's stock worth $2,830,000 after acquiring an additional 2,211 shares during the last quarter. Illumine Investment Management LLC lifted its stake in shares of United Therapeutics by 0.7% during the 1st quarter. Illumine Investment Management LLC now owns 8,604 shares of the biotechnology company's stock worth $2,652,000 after acquiring an additional 58 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of United Therapeutics by 17.9% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 226,287 shares of the biotechnology company's stock worth $69,757,000 after acquiring an additional 34,362 shares during the last quarter. Finally, Diversified Trust Co lifted its stake in shares of United Therapeutics by 139.8% during the 1st quarter. Diversified Trust Co now owns 1,842 shares of the biotechnology company's stock worth $568,000 after acquiring an additional 1,074 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Down 0.1%

Shares of NASDAQ:UTHR opened at $432.69 on Tuesday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48. The business's fifty day simple moving average is $388.34 and its 200-day simple moving average is $329.17. The company has a market capitalization of $19.52 billion, a PE ratio of 16.89, a P/E/G ratio of 4.72 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the business posted $5.85 earnings per share. The company's revenue was up 11.7% compared to the same quarter last year. Research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on UTHR. UBS Group raised their price target on United Therapeutics from $560.00 to $580.00 and gave the stock a "buy" rating in a research note on Monday, September 29th. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Wells Fargo & Company began coverage on United Therapeutics in a report on Monday. They set an "underweight" rating and a $414.00 price objective on the stock. Royal Bank Of Canada began coverage on United Therapeutics in a report on Friday, September 26th. They set an "outperform" rating and a $569.00 price objective on the stock. Finally, Morgan Stanley raised their price objective on United Therapeutics from $328.00 to $435.00 and gave the stock an "equal weight" rating in a report on Friday, October 10th. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $461.62.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 307,435 shares of company stock worth $125,401,167 over the last quarter. Company insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.